145 related articles for article (PubMed ID: 32063772)
21. Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab.
Gay ND; Okada CY; Chen AI; Scott EC
Ther Adv Hematol; 2017 May; 8(5):175-180. PubMed ID: 28473905
[TBL] [Abstract][Full Text] [Related]
22. Two primary cancers appeared after discontinuation of nivolumab in the course of treating Hodgkin lymphoma: a case report.
Potluri LB; Nanjareddy S; Al Sbihi A; Manasrah N; Smith W; Sano D
AME Case Rep; 2023; 7():30. PubMed ID: 37492791
[TBL] [Abstract][Full Text] [Related]
23. Experience of Nivolumab Prior to Autologous Stem Cell Transplant for Relapsed Refractory Hodgkin Lymphoma.
Patel J; Garg A; Patel K; Shah K; Shah S; Yadav R; Anand A; Panchal H; Patel A; Parikh S; Shah S
Indian J Hematol Blood Transfus; 2022 Jul; 38(3):585-590. PubMed ID: 35747573
[No Abstract] [Full Text] [Related]
24. Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails.
Zhou H; Fu X; Li Q; Niu T
Front Pharmacol; 2019; 10():387. PubMed ID: 31118893
[No Abstract] [Full Text] [Related]
25. Loss of nivolumab binding to T cell PD-1 predicts relapse of Hodgkin lymphoma.
Ogasawara R; Hashimoto D; Sugita J; Yamawaki F; Naka T; Mitsuhashi T; Takahashi S; Miyashita N; Okada K; Onozawa M; Matsuno Y; Teshima T
Int J Hematol; 2020 Mar; 111(3):475-479. PubMed ID: 31538325
[TBL] [Abstract][Full Text] [Related]
26. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient?
Özyurt E; Özçelik S; Sürmeli H; Çelik M; Ayhan M; Özçelik M
J Oncol Pharm Pract; 2022 Mar; 28(2):462-465. PubMed ID: 34558355
[TBL] [Abstract][Full Text] [Related]
27. Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma.
Foran AE; Nadel HR; Lee AF; Savage KJ; Deyell RJ
J Pediatr Hematol Oncol; 2017 Jul; 39(5):e263-e266. PubMed ID: 27841828
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
Onizuka M; Kojima M; Matsui K; Machida S; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Nakamura N; Ando K
Int J Hematol; 2017 Jul; 106(1):141-145. PubMed ID: 28097534
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab induced myxedema crisis.
Khan U; Rizvi H; Sano D; Chiu J; Hadid T
J Immunother Cancer; 2017; 5():13. PubMed ID: 28239466
[TBL] [Abstract][Full Text] [Related]
30. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
[TBL] [Abstract][Full Text] [Related]
31. Sanctuary site central nervous system relapse-refractory DLBCL responding to nivolumab and lenalidomide.
Madabhavi IV; Revannasiddaiah S; Sarkar MS; Modi MG
Oral Oncol; 2019 Jun; 93():122-124. PubMed ID: 31010638
[TBL] [Abstract][Full Text] [Related]
32. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
33. A Case Report of Steroid Responsive Nivolumab-Induced Encephalitis.
Richard K; Weslow J; Porcella SL; Nanjappa S
Cancer Control; 2017; 24(5):1073274817729069. PubMed ID: 28975824
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Goldkuhle M; Dimaki M; Gartlehner G; Monsef I; Dahm P; Glossmann JP; Engert A; von Tresckow B; Skoetz N
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD012556. PubMed ID: 30001476
[TBL] [Abstract][Full Text] [Related]
35. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
36. Nivolumab in relapsed/refractory Hodgkin lymphoma: towards a new treatment strategy?
Cencini E; Bocchia M; Fabbri A
Am J Blood Res; 2021; 11(3):261-265. PubMed ID: 34322289
[TBL] [Abstract][Full Text] [Related]
37. Delayed immune thrombocytopenia after discontinuation of nivolumab therapy: A case report and literature review.
Fu S; Wang T; Xu F
J Oncol Pharm Pract; 2021 Sep; 27(6):1548-1552. PubMed ID: 33435825
[TBL] [Abstract][Full Text] [Related]
38. Very high-dose methylprednisolone for treatment of nivolumab-induced limbic encephalitis: A case report.
Taillefer VT; Pigeon M; Chen M; Larochelle C; Florescu M; Bélanger K; Adam JP
J Oncol Pharm Pract; 2020 Sep; 26(6):1538-1543. PubMed ID: 32063105
[TBL] [Abstract][Full Text] [Related]
39. Late-onset double-seronegative myasthenia gravis syndrome and myasthenic crisis due to nivolumab use for Hodgkin's lymphoma.
Dang T; Macwan S; Dasanu CA
J Oncol Pharm Pract; 2021 Sep; 27(6):1534-1538. PubMed ID: 33292071
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
